RGNX Key Statistics, Chart & Performance
The current stock price of RGNX is 11.6 USD. In the past month the price decreased by -17.67%. In the past year, price increased by 43.74%.
RGNX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RGNX. When comparing the yearly performance of all stocks, RGNX is one of the better performing stocks in the market, outperforming 77.77% of all stocks.
RGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RGNX. RGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RGNX Financial Highlights
Over the last trailing twelve months RGNX reported a non-GAAP Earnings per Share(EPS) of -3.47. The EPS increased by 30.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.88% | ||
| ROE | -110.2% | ||
| Debt/Equity | 0 |
RGNX Forecast & Estimates
19 analysts have analysed RGNX and the average price target is 33.42 USD. This implies a price increase of 188.14% is expected in the next year compared to the current price of 11.6.
For the next year, analysts expect an EPS growth of 32.51% and a revenue growth 110.32% for RGNX
RGNX Ownership
RGNX Latest News, Press Relases and Analysis
About RGNX
Company Profile
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 353 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Company Info
REGENXBIO INC
9804 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Kenneth T. Mills
Employees: 353
Phone: 12405528181
REGENXBIO INC / RGNX FAQ
What does REGENXBIO INC do?
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 353 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
What is the current price of RGNX stock?
The current stock price of RGNX is 11.6 USD. The price increased by 5.36% in the last trading session.
What is the dividend status of REGENXBIO INC?
RGNX does not pay a dividend.
What is the ChartMill rating of REGENXBIO INC stock?
RGNX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists RGNX stock?
RGNX stock is listed on the Nasdaq exchange.
Is REGENXBIO INC (RGNX) expected to grow?
The Revenue of REGENXBIO INC (RGNX) is expected to grow by 110.32% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for REGENXBIO INC?
REGENXBIO INC (RGNX) has a market capitalization of 587.19M USD. This makes RGNX a Small Cap stock.